Starling Registry Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,207
- 试验地点
- 3
- 主要终点
- 30 day in-hospital mortality rate
研究概览
简要总结
Hemodynamic optimization of critically ill patients is a goal for clinicians in order to afford the patient the best possible outcomes. Being able to precisely and rapidly determine patient fluid responsiveness provides the bedside physician and nursing staff the information needed to make critical decisions in regards to the patient's fluid status and management of additional fluids and medications.
As fluid management and cardiac output determination are linked to better decision-making and improved outcomes in ICU, the use of a dynamic assessment of fluid responsiveness becomes a key tool for patient management.
This study is designed to collect treatment and outcome data on patients that have undergone hemodynamic monitoring in a wide variety of clinical settings, involving a variety of patient diagnoses.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 95 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18 to 95 years of age
- •Patient has undergone hemodynamic monitoring with the Starling monitor
- •Hemodynamic monitoring was completed no earlier than 2018
排除标准
- 未提供
结局指标
主要结局
30 day in-hospital mortality rate
时间窗: Day 1 to Day 30
Number of days in Hospital
时间窗: Day 1 to Day 30
Volume of treatment fluid administered
时间窗: Time of monitoring to completion
Number of days on vasopressors
时间窗: Day 1 to Day 30
Number of participants needing mechanical ventilation
时间窗: Time of monitoring to completion
Lactate level
时间窗: Time of monitoring to completion
Number of days in Intensive Care Unit (ICU)
时间窗: Day 1 to Day 30
次要结局
- Number of participants with COVID-19(Time of monitoring to completion)
- Percent of participants that are fluid responsive(Time of monitoring to completion)
- Percent of participants with fluid responsiveness in diastolic dysfunction(Time of monitoring to completion)
- Number of participants with device related Serious Adverse Events(Time of monitoring to completion)
- Number of participants with COVID-19 by treatment type(Time of monitoring to completion)
- Number of participants with COVID-19 by outcome type(Time of monitoring to completion)
- Number of participants with diastolic dysfunction(Time of monitoring to completion)
- Number of participants with device related Non-Serious Adverse Events(Time of monitoring to completion)